JP7416355B2 - 選択マーカー発現カセット - Google Patents
選択マーカー発現カセット Download PDFInfo
- Publication number
- JP7416355B2 JP7416355B2 JP2023506894A JP2023506894A JP7416355B2 JP 7416355 B2 JP7416355 B2 JP 7416355B2 JP 2023506894 A JP2023506894 A JP 2023506894A JP 2023506894 A JP2023506894 A JP 2023506894A JP 7416355 B2 JP7416355 B2 JP 7416355B2
- Authority
- JP
- Japan
- Prior art keywords
- expression
- sequence dna
- sequence
- selection marker
- tdna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000014509 gene expression Effects 0.000 title claims description 75
- 239000003550 marker Substances 0.000 title claims description 50
- 108020004414 DNA Proteins 0.000 claims description 95
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 238000011144 upstream manufacturing Methods 0.000 claims description 46
- 239000013604 expression vector Substances 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 108091081024 Start codon Proteins 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 239000012212 insulator Substances 0.000 claims description 23
- 108020004566 Transfer RNA Proteins 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 6
- 229930024421 Adenine Natural products 0.000 claims description 3
- 229960000643 adenine Drugs 0.000 claims description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 3
- 229940022353 herceptin Drugs 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 26
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 24
- 230000014616 translation Effects 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 238000013519 translation Methods 0.000 description 14
- 239000002609 medium Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 229950010131 puromycin Drugs 0.000 description 12
- 239000012634 fragment Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 238000012215 gene cloning Methods 0.000 description 4
- 239000012124 Opti-MEM Substances 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000007702 DNA assembly Methods 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 238000012815 AlphaLISA Methods 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021041250 | 2021-03-15 | ||
| JP2021041250 | 2021-03-15 | ||
| PCT/JP2022/006667 WO2022196245A1 (ja) | 2021-03-15 | 2022-02-18 | 選択マーカー発現カセット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022196245A1 JPWO2022196245A1 (https=) | 2022-09-22 |
| JPWO2022196245A5 JPWO2022196245A5 (https=) | 2023-09-07 |
| JP7416355B2 true JP7416355B2 (ja) | 2024-01-17 |
Family
ID=83322300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023506894A Active JP7416355B2 (ja) | 2021-03-15 | 2022-02-18 | 選択マーカー発現カセット |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP7416355B2 (https=) |
| WO (1) | WO2022196245A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117947040A (zh) * | 2022-10-31 | 2024-04-30 | 苏州荷光科汇生物科技有限公司 | 用于目的基因的表达盒及其应用 |
| WO2025059168A1 (en) * | 2023-09-12 | 2025-03-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Hsv vectors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2258843T3 (en) * | 2008-02-27 | 2017-02-13 | Nat Univ Corp Hokkaido Univ | Expression vector with mass production of foreign gene-derived protein by animal cells and use thereof |
| AU2012203048A1 (en) * | 2011-05-24 | 2012-12-13 | Agency For Science, Technology And Research | IRES mediated multicistronic vectors |
-
2022
- 2022-02-18 JP JP2023506894A patent/JP7416355B2/ja active Active
- 2022-02-18 WO PCT/JP2022/006667 patent/WO2022196245A1/ja not_active Ceased
Non-Patent Citations (3)
| Title |
|---|
| FERREIRA Joshua P et al.，Engineering ribosomal leaky scanning and upstream open reading frames for precise control of protein translation，Bioengineered，2014年，Vol.5, issue3，p.186-192 |
| GATHER Fabian et al.，Regulation of human inducible nitric oxide synthase expression by an upstream open reading frame，Nitric Oxide，2019年，Vol.88，p.50-60 & Supplemental Figures |
| NADERI Fatemeh et al.，The Augmenting Effects of the tDNA Insulator on Stable Expression of Monoclonal Antibody in Chinese Hamster Ovary Cells，MONOCLONAL ANTIBODIES IN IMMUNODIAGNOSIS AND IMMUNOTHERAPY，2018年，Vol.37, No.5，p.200-206 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022196245A1 (ja) | 2022-09-22 |
| JPWO2022196245A1 (https=) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2386644B1 (en) | Expression system | |
| US12215335B2 (en) | Non-integrating DNA vectors for the genetic modification of cells | |
| CN109072257B (zh) | 增强的睡美人转座子、试剂盒和转座方法 | |
| JP7416355B2 (ja) | 選択マーカー発現カセット | |
| US20180245057A1 (en) | Systems and methods for selection of grna targeting strands for cas9 localization | |
| JP7636328B2 (ja) | １つまたは複数の非天然尾部繊維を有する非複製的形質導入粒子および形質導入粒子ベースのレポーターシステム | |
| US11060108B2 (en) | DNA element having the activity of enhancing foreign gene expression | |
| KR102755545B1 (ko) | 프로모터 | |
| Underhill et al. | Transient gene expression levels from multigene expression vectors | |
| CN107532178A (zh) | 用于自诱导蛋白表达的方法和系统 | |
| KR20250166294A (ko) | 단리된 뉴클레아제 및 이의 용도 | |
| CN102296087B (zh) | 基于枯草芽孢杆菌生物素连接酶的外源基因诱导表达调控系统及其构建方法 | |
| JP6779513B2 (ja) | インビボクローニング可能な細胞株をスクリーニングするための方法、インビボクローニング可能な細胞株の製造方法、細胞株、インビボクローニング方法、及びインビボクローニングを行うためのキット | |
| Mursi et al. | The production of recombinant proteins from mammalian cells using RNA element | |
| Krause et al. | Efficient co-expression of bicistronic proteins in mesenchymal stem cells by development and optimization of a multifunctional plasmid | |
| Zha et al. | One-step construction of lentiviral reporter using red-mediated recombination | |
| TW202146432A (zh) | 新基因表現單元 | |
| WO2019093418A1 (ja) | 哺乳動物細胞内の標的染色体部位で目的遺伝子を含むポリヌクレオチドを増幅させる方法およびベクター、ならびにその利用 | |
| HK1258956B (en) | Enhanced sleeping beauty transposons, kits and methods of transposition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230528 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230730 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230730 |
|
| AA64 | Notification of invalidation of claim of internal priority (with term) |
Free format text: JAPANESE INTERMEDIATE CODE: A241764 Effective date: 20230804 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230811 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231104 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231219 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231219 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7416355 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |